title: The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.
abstract: Immunohistochemical analyses of the effects of hepatocyte growth factor (HGF) and c-Met expression on tumour growth and angiogenesis were performed on 88 patients with non-small-cell lung cancers (NSCLCs). In all, 22 carcinomas (25.0%) were intratumoral HGF-positive, 14 carcinomas (15.9%) were stromal HGF-positive, and 36 carcinomas (40.9%) were intratumoral c-Met-positive. None of the carcinomas were stromal c-Met-positive. Examination of tumour growth revealed that the frequency of tumours with a high Ki-67 index was significantly greater for stromal HGF-positive tumours than for stromal HGF-negative tumours (P=0.0197). The frequency of tumours with a high Ki-67 index was also significantly greater for intratumoral c-Met-positive tumours than for intratumoral c-Met-negative tumours (P=0.0301). However, there was no significant difference in tumour vascularity with relation to intratumoral HGF status, stromal HGF status, and intratumoral c-Met status. The survival rate of patients with intratumoral c-Met-positive tumours was significantly lower than for patients with c-Met-negative tumours (P=0.0095). Furthermore, the survival rate of patients with both intratumoral c-Met-positive and stromal HGF-positive tumours was significantly lower than for patients with either positive tumours, and that of patients with both negative tumours (P=0.0183 and P=0.0011, respectively). A univariate analysis revealed that intratumoral c-Met expression was a significant prognostic factor of NSCLC patients (relative risk=2.642, P=0.0029). The present study demonstrates that tumour-stromal interaction between tumour cell-derived c-Met and stromal cell-derived HGF affects tumour growth and the prognosis of NSCLC patients.
authors.affiliation: Second Department of Surgery, Kagawa Medical University, 1750-1 Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Masuya
authors.forename: C
authors.initials: C
authors.lastname: Huang
authors.forename: D
authors.initials: D
authors.lastname: Liu
authors.forename: T
authors.initials: T
authors.lastname: Nakashima
authors.forename: K
authors.initials: K
authors.lastname: Kameyama
authors.forename: R
authors.initials: R
authors.lastname: Haba
authors.forename: M
authors.initials: M
authors.lastname: Ueno
authors.forename: H
authors.initials: H
authors.lastname: Yokomise
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D002450:Cell Communication; D002455:Cell Division; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D017228:Hepatocyte Growth Factor / Q000032:analysis / Q000096:biosynthesis* / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008175:Lung Neoplasms / Q000473:pathology*; D009389:Neovascularization, Pathologic; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis / Q000096:biosynthesis* / Q000494:pharmacology*; D017154:Stromal Cells / Q000502:physiology*; D016019:Survival Analysis
chemical_list: D019394:Ki-67 Antigen; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met